Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

The Time Has Come!

Tempero M.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):295. doi: 10.6004/jnccn.2019.0020. No abstract available.

PMID:
30959464
2.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
3.

Kids, There's an App for That!

Tempero M.

J Natl Compr Canc Netw. 2019 Feb;17(2):101. doi: 10.6004/jnccn.2019.0010. No abstract available.

PMID:
30787121
4.

New Year, New Look!

Tempero M.

J Natl Compr Canc Netw. 2019 Jan;17(1):1. doi: 10.6004/jnccn.2019.0003. No abstract available.

PMID:
30659122
5.

Pancreas Cancer-Associated Weight Loss.

Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L; Precision Promise Consortium.

Oncologist. 2018 Dec 27. pii: theoncologist.2018-0266. doi: 10.1634/theoncologist.2018-0266. [Epub ahead of print]

PMID:
30591550
6.

An Oncologist's Letter to Santa: Bring Me Drugs!

Tempero M.

J Natl Compr Canc Netw. 2018 Dec;16(12):1411. doi: 10.6004/jnccn.2018.0090. No abstract available.

PMID:
30545986
7.

I'm Conflicted. Are You?

Tempero M.

J Natl Compr Canc Netw. 2018 Nov;16(11):1273. doi: 10.6004/jnccn.2018.0085. No abstract available.

PMID:
30442729
8.

One Size Fits All? Really?

Tempero M.

J Natl Compr Canc Netw. 2018 Oct;16(10):1161. doi: 10.6004/jnccn.2018.0080. No abstract available.

PMID:
30323084
9.

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.

Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.

PMID:
30267352
10.

Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?

Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE.

Am J Surg Pathol. 2019 Mar;43(3):334-340. doi: 10.1097/PAS.0000000000001152.

PMID:
30211728
11.

Getting What You Pay For: Finding Value in Cancer Care.

Tempero M.

J Natl Compr Canc Netw. 2018 Sep;16(9):1031. doi: 10.6004/jnccn.2018.0077. No abstract available.

PMID:
30181413
12.

Notes From the Other Side.

Tempero M.

J Natl Compr Canc Netw. 2018 Aug;16(8):921-922. doi: 10.6004/jnccn.2018.0068. No abstract available.

PMID:
30099366
13.

Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.

Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA.

AJR Am J Roentgenol. 2018 Nov;211(5):1010-1019. doi: 10.2214/AJR.18.19602. Epub 2018 Jul 31.

PMID:
30063366
14.

Genomic Medicine Takes the Stage, Again!

Tempero M.

J Natl Compr Canc Netw. 2018 Jul;16(7):795. doi: 10.6004/jnccn.2018.0063. No abstract available.

PMID:
30006420
15.

Movin' On Up!

Tempero M.

J Natl Compr Canc Netw. 2018 Jun;16(6):675. doi: 10.6004/jnccn.2018.0057. No abstract available.

PMID:
29891517
16.

Getting Into the Weeds.

Tempero M.

J Natl Compr Canc Netw. 2018 May;16(5):457. doi: 10.6004/jnccn.2018.0027. No abstract available.

PMID:
29752317
17.

Standing Together or Alone.

Tempero M.

J Natl Compr Canc Netw. 2018 Apr;16(4):341. doi: 10.6004/jnccn.2018.0022. No abstract available.

PMID:
29632051
18.

Molecular Diagnostics: Another Battle Brewing.

Tempero M.

J Natl Compr Canc Netw. 2018 Mar;16(3):225. doi: w10.6004/jnccn.2018.0015. No abstract available.

PMID:
29523658
19.

Extending Our Reach-Will Telemedicine Get Us There?

Tempero M.

J Natl Compr Canc Netw. 2018 Feb;16(2):107. doi: 10.6004/jnccn.2018.0008. No abstract available.

PMID:
29439170
20.

Revisiting New Year's Resolutions.

Tempero M.

J Natl Compr Canc Netw. 2018 Jan;16(1):1. doi: 10.6004/jnccn.2018.0003. No abstract available.

PMID:
29295874
21.

HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.

Doherty GJ, Tempero M, Corrie PG.

Future Oncol. 2018 Jan;14(1):13-22. doi: 10.2217/fon-2017-0338. Epub 2017 Oct 23.

PMID:
29235360
22.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

23.

It's About Time!

Tempero M.

J Natl Compr Canc Netw. 2017 Dec;15(12):1443. doi: 10.6004/jnccn.2017.0177. No abstract available.

PMID:
29223979
24.

Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies.

Tempero MA.

Cancer J. 2017 Nov/Dec;23(6):309. doi: 10.1097/PPO.0000000000000295. Review. No abstract available.

PMID:
29189324
25.

Who's Watching the Kids?

Tempero M.

J Natl Compr Canc Netw. 2017 Nov;15(11):1289. doi: 10.6004/jnccn.2017.0170. No abstract available.

PMID:
29118220
26.

Serving "a la CAR-T": Value-Based Pricing and Gene Therapy.

Tempero M.

J Natl Compr Canc Netw. 2017 Oct;15(10):1179. doi: 10.6004/jnccn.2017.0162. No abstract available.

PMID:
28982741
27.

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS 4th, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC.

Oncologist. 2017 Dec;22(12):1427-e129. doi: 10.1634/theoncologist.2017-0066. Epub 2017 Sep 21.

28.

Your Genes: Getting the Best Fit.

Tempero M.

J Natl Compr Canc Netw. 2017 Sep;15(9):1083. doi: 10.6004/jnccn.2017.0152. No abstract available.

PMID:
28874592
29.

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.

Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network.

Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.

30.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
31.

When It's Really Good, We Know It!

Tempero M.

J Natl Compr Canc Netw. 2017 Aug;15(8):973. doi: 10.6004/jnccn.2017.0141. No abstract available.

PMID:
28784856
32.

Reducing the Cost of Cancer Care: When Less Is More.

Tempero M.

J Natl Compr Canc Netw. 2017 Jul;15(7):853. doi: 10.6004/jnccn.2017.0125. No abstract available.

PMID:
28687571
33.

Getting Practical About Recertification.

Tempero M.

J Natl Compr Canc Netw. 2017 Jun;15(6):753. doi: 10.6004/jnccn.2017.0110. No abstract available.

PMID:
28596253
34.

Active Systemic Treatment of Pancreatic Cancer.

Tempero M.

J Natl Compr Canc Netw. 2017 May;15(5S):723-725.

PMID:
28515255
35.

Hospice: Angels at Work.

Tempero M.

J Natl Compr Canc Netw. 2017 May;15(5):549. No abstract available.

PMID:
28476733
36.

Politics as Usual-Not!

Tempero M.

J Natl Compr Canc Netw. 2017 Apr;15(4):425. No abstract available.

PMID:
28404753
37.

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw266.

38.

Saying Yes.

Tempero M.

J Natl Compr Canc Netw. 2017 Mar;15(3):277. No abstract available.

PMID:
28275029
39.

Mad About MACRA.

Tempero M.

J Natl Compr Canc Netw. 2017 Feb;15(2):137. No abstract available.

PMID:
28188184
40.

New Year's Resolutions.

Tempero M.

J Natl Compr Canc Netw. 2017 Jan;15(1):1. No abstract available.

PMID:
28040714
41.

An Oncologist's Letter to Santa.

Tempero M.

J Natl Compr Canc Netw. 2016 Dec;14(12):1491. No abstract available.

PMID:
27956532
42.

Assessing Researcher Needs for a Virtual Biobank.

van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S.

Biopreserv Biobank. 2017 Jun;15(3):203-210. doi: 10.1089/bio.2016.0009. Epub 2016 Dec 8.

43.

Hypermutation In Pancreatic Cancer.

Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Gr├╝tzmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV.

Gastroenterology. 2017 Jan;152(1):68-74.e2. doi: 10.1053/j.gastro.2016.09.060. Epub 2016 Nov 15.

PMID:
27856273
44.

My Knee Hurts!

Tempero M.

J Natl Compr Canc Netw. 2016 Nov;14(11):1335. No abstract available.

PMID:
27799504
45.

Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?

Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH.

J Surg Oncol. 2016 Oct;114(5):587-596. doi: 10.1002/jso.24375. Epub 2016 Jul 21.

PMID:
27444658
46.

Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.

Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK.

Pancreas. 2016 Nov;45(10):1394-1400.

PMID:
27171514
47.

Crossing the Line.

Tempero M.

J Natl Compr Canc Netw. 2016 Oct;14(10):1191. No abstract available.

PMID:
27697973
48.

Hillary and Donald, Our Patients Are Watching.

Tempero M.

J Natl Compr Canc Netw. 2016 Sep;14(9):1047. No abstract available.

PMID:
27587617
49.

I'll Have Another Shot, Please!

Tempero M.

J Natl Compr Canc Netw. 2016 Aug;14(8):929. No abstract available.

PMID:
27496107
50.

The Greatest Show on Earth!

Tempero M.

J Natl Compr Canc Netw. 2016 Jul;14(7):813. No abstract available.

PMID:
27407120

Supplemental Content

Loading ...
Support Center